DrugBiological
Nivolumab clinical trials
Also written Opdivo, BMS-936558 and ONO-4538.
- studies test it
- 1,111
- open now
- 176
- in phase 3
- 114
- first study started
- 2006
Keep track of what changes. Save the Nivolumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
- Opdivo
- 604
Development codes
Combined with it in one product
Biosimilars in development
- BCD-263
- 4
- ABP 206
- 2
- CMAB819
- 1
Studies by the year they started
1,109 studies that test it; most in 2018 (159); 1 more planned to start later
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 8 |
| 2013 | 9 |
| 2014 | 22 |
| 2015 | 49 |
| 2016 | 95 |
| 2017 | 152 |
| 2018 | 159 |
| 2019 | 158 |
| 2020 | 123 |
| 2021 | 86 |
| 2022 | 71 |
| 2023 | 48 |
| 2024 | 41 |
| 2025 | 43 |
| 2026 | 40 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 24
- Phase 1
- 415
- Phase 2
- 737
- Phase 3
- 114
- Phase 4
- 12
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 296 · Other 815
Bristol-Myers Squibb (142) · National Cancer Institute (NCI) (67) · M.D. Anderson Cancer Center (50) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (24) · H. Lee Moffitt Cancer Center and Research Institute (23) · Memorial Sloan Kettering Cancer Center (20) · Dana-Farber Cancer Institute (17) · Emory University (14)
Often tested with
Tested in the same studies.
Ipilimumab (290) · Pembrolizumab (52) · Relatlimab (34) · Paclitaxel (30) · Cabozantinib (28) · Cisplatin (26) · Gemcitabine (26) · Carboplatin (20)
Studies
Open first, then newest update. How each study uses Nivolumab is read from its arms, and is right about nine times in ten.
Testing it · 1,111
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3Bristol-Myers SquibbNCT06561386Written as Nivolumab
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingPhase 2National Cancer Institute (NCI)NCT05136196Written as Nivolumab
- Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint InhibitorsRecruitingPhase 1Washington University School of MedicineNCT05629546Written as Nivolumab
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Nivolumab
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialRecruitingPhase 2/3National Cancer Institute (NCI)NCT06203600Written as Nivolumab
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382Written as Nivolumab
- Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based TreatmentRecruitingPhase 2Maria Sklodowska-Curie National Research Institute of OncologyNCT04875611Written as Opdivo
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerRecruitingPhase 2Gilead SciencesNCT07527858Written as Nivolumab
- Axelopran and Nivolumab in PD-1-Refractory Metastatic MelanomaRecruitingPhase 1/2John KirkwoodNCT07631325Written as Nivolumab
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingPhase 2National Cancer Institute (NCI)NCT03258567Written as Nivolumab
- Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVRecruitingPhase 1National Cancer Institute (NCI)NCT04902443Written as Nivolumab
- Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT07460765Written as Nivo800
- A Study of Treatment Delivery Preference In People With Kidney CancerRecruitingPhase 4Memorial Sloan Kettering Cancer CenterNCT07872553Written as Nivolumab Injectable Product
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT05896839Written as Nivolumab
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)RecruitingPhase 2National Cancer Institute (NCI)NCT06064097Written as Nivolumab
- Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingPhase 2Mark BernardNCT07770100Written as Nivolumab
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaRecruitingPhase 1/2Perspective TherapeuticsNCT05655312Written as Nivolumab
- Neoadjuvant RP2 + Nivolumab in Patients With MelanomaNot yet recruitingPhase 2Yana NajjarNCT07862530Written as Nivolumab
- Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06053658Written as Nivolumab
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07430202Written as Nivolumab
See all 1,111 studies that test Nivolumab →
Given in every arm · 398 — Nivolumab is usual care beside what is tested
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686Written as Nivolumab
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruitingPhase 2/3National Cancer Institute (NCI)NCT05987241Written as Nivolumab
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT05112601Written as Nivolumab
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06029270Written as Nivolumab
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07405164Written as Nivolumab
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Nivolumab
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Nivolumab
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2RecruitingPhase 3AstraZenecaNCT07431281Written as Nivolumab
- ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT04566380Written as ONO-4538
- Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesRecruitingPhase 1/2Melanoma and Skin Cancer Trials LimitedNCT06163820Written as Nivolumab
- Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsRecruitingPhase 3InSightecNCT05317858Written as Nivolumab
- Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk MelanomaRecruitingPhase 2University Health Network, TorontoNCT06319196Written as Nivolumab
- Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)RecruitingPhase 2Melanoma Institute AustraliaNCT03340129Written as Nivolumab
- A Study of TRK-950 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Toray Industries, IncNCT05423262Written as Nivolumab
- FOG-001 in Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Parabilis Medicines, Inc.NCT05919264Written as Nivolumab
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 2Bristol-Myers SquibbNCT07492680Written as Nivolumab + Relatlimab FDC
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345Written as Nivolumab
- Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Groupe Oncologie Radiotherapie Tete et CouNCT07529873Written as Nivolumab
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04991025Written as Nivolumab
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT05677490Written as Nivolumab
Showing 20 of 398.
As the comparator · 33 — what is tested is compared with Nivolumab
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingPhase 3Boehringer IngelheimNCT07195695Written as Nivolumab
- A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 3Hoffmann-La RocheNCT07541170Written as Nivolumab
- Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerRecruitingPhase 2/3PfizerNCT07392892Written as Nivolumab
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingPhase 3Regeneron PharmaceuticalsNCT06246916Written as relatlimab+nivolumab
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingPhase 3AkesoNCT07700979Written as Nivolumab
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2Brian RiniNCT07188896Written as Nivolumab
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126Written as nivolumab plus relatlimab
- A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid TumorsRecruitingPhase 1Shanghai Henlius BiotechNCT07518043Written as OPDIVO®
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingPhase 3AstraZenecaNCT07720284Written as Nivolumab
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]RecruitingPhase 3Replimune, Inc.NCT06264180Written as Nivolumab
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)Not yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07672223Written as Nivolumab
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingPhase 3Centre Leon BerardNCT06346197Written as Nivolumab
- 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCCRecruitingPhase 2Barbara BurtnessNCT05317000Written as Nivolumab
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)RecruitingPhase 3Immunocore LtdNCT06112314Written as Nivolumab
- Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLCRecruitingPhase 2Fudan UniversityNCT07398937Written as Nivolumab + chemotherapy
- Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedRecruitingPhase 3Intergroupe Francophone de Cancerologie ThoraciqueNCT06908993Written as Nivolumab
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaActive, not recruitingPhase 3AstraZenecaNCT06097728Written as Nivolumab
- A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaActive, not recruitingPhase 3Shandong Boan Biotechnology Co., LtdNCT06022861Written as Opdivo®
- A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadActive, not recruitingPhase 3Bristol-Myers SquibbNCT04810078Written as Nivolumab
- Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop TrialActive, not recruitingPhase 2ECOG-ACRIN Cancer Research GroupNCT04462406Written as Nivolumab
Showing 20 of 33.
Codes
What other systems call Nivolumab · ClinicalTrials.gg INT006768
- MeSH (NLM) D000077594NivolumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 31YO63LBSNNIVOLUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1597876Confirmed FDA, Wikidata
- Wikidata Q7041828nivolumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68814NivolumabOne source FDA
- DrugBank DB09035One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077594 | Nivolumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 31YO63LBSN | NIVOLUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1597876 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7041828 | nivolumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68814 | Nivolumab | One source FDA |
| DrugBank | DB09035 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.